Pantop%25252525252525252525252525252525252520d

# Pantoprazole ## Overview Pantoprazole is a substituted benzimidazole proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly inhibiting the H+/K+-ATPase enzyme system at the secretory surface of the gastric parietal cell. ## Primary Indications * Short-term treatment of erosive esophagitis associated with GERD. * Maintenance of healing of erosive esophagitis. * Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome). * Prophylaxis of stress-induced upper GI bleeding (off-label/institutional protocol). ## Adult Dosing * **GERD/Erosive Esophagitis:** 40 mg PO or IV once daily for up to 8 weeks. * **Maintenance:** 40 mg PO once daily. * **Hypersecretory Conditions:** Starting dose 40 mg PO twice daily. Doses up to 240 mg/day have been utilized; titration based on clinical response. * **IV Prophylaxis/Treatment (Refractory GERD):** 40 mg IV daily or every 12 hours. ## Pediatric Dosing * **Erosive Esophagitis (5 years and older):** * 15 kg to < 40 kg: 20 mg PO once daily. * ≥ 40 kg: 40 mg PO once daily. * *Note: Safety and efficacy for IV administration in children have not been established.* ## Dose Adjustments * **Renal Impairment:** No dosage adjustment necessary. * **Hepatic Impairment:** No standard adjustment, but monitor liver enzymes if cirrhosis is present. Maximum dose in severe hepatic impairment should be monitored closely. ## Contraindications * Hypersensitivity to pantoprazole or any component of the formulation. * Concomitant use with rilpivirine-containing products (due to decreased absorption). ## Adverse Effects * **Common:** Headache, diarrhea, nausea, abdominal pain. * **Serious:** *Clostridioides difficile*-associated diarrhea, hypomagnesemia, vitamin B12 deficiency (with long-term use), acute interstitial nephritis, cutaneous/systemic lupus erythematosus. ## Key Drug Interactions * **pH-Dependent Drugs:** Decreases absorption of atazanavir, nelfinavir, iron salts, and certain azole antifungals (e.g., ketoconazole). * **Methotrexate:** Potential for increased serum levels and toxicity, especially in high-dose therapy. * **Warfarin:** Potential for increased INR/prothrombin time; monitor closely when initiating or stopping PPI therapy. ## Monitoring * **Baseline/Long-term:** Monitor magnesium levels if on long-term therapy or concomitant diuretics. * **Symptom Resolution:** Evaluate need for continued therapy periodically. * **Renal:** Monitor for signs of interstitial nephritis (rare). ## Clinical Pearls * **Administration:** Tablets should be swallowed whole; do not crush or chew. IV administration should be a 15-minute infusion or a 2-minute slow injection. * **Tapering:** Long-term users may experience rebound hypersecretion upon discontinuation; consider a gradual taper. * **Stress Ulcer Prophylaxis:** Use only when indicated, as inappropriate PPI use increases risks of hospital-acquired pneumonia and *C. diff* infection. * **Bioavailability:** IV to PO transition is 1:1. *** **Disclaimer:** This information is for educational purposes only. Clinical practice guidelines vary by institution. Always verify current prescribing information, institutional protocols, and patient-specific factors via reliable clinical resources (e.g., Lexicomp, Micromedex, or package inserts) before prescribing or administering medication.